Business Overview

Dey, a subsidiary of Mylan Inc. (NASDAQ: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, severe allergic reactions and psychiatric disorders.

Dey has a long history of providing high quality drug products and has enjoyed significant growth in sales, manufacturing capacity and personnel. Over time, Dey has expanded its product portfolio to include products, such as Perforomist® Inhalation Solution, EpiPen® Auto-Injector and EMSAM® (selegiline transdermal system).

Dey markets its products in the U.S. through a dedicated sales force that sells to office-based physicians, hospitals and distribution chain organizations. Dey markets its products outside the U.S. through a network of distributors, some of which are Dey affiliates.

Dey facilities are located in New Jersey, California, and Texas.

Founded as Dey Laboratories in 1978 as a generic drug manufacturer, the company began to develop a portfolio of airway and allergy medications. Ten years later, Dey Laboratories became a subsidiary of Lipha S.A. (Lyon, France), and in 1991, Merck KGaA (Darmstadt, Germany) acquired a majority share of Lipha S.A. Eventually, Dey Laboratories evolved into Dey.

In 2007, Mylan acquired Merck KGaA's generics business and Dey became part of the Mylan family. On Sept. 10, 2009, Dey, L.P. changed its legal name to Dey Pharma, L.P.

Dey Core Competencies

Leadership position in U.S. nebulized respiratory market and worldwide severe allergy and psychiatric markets
Demonstrated ability to successfully market and grow branded products
Proven ability to understand market needs
Experienced sales force focused on speciality products
High quality standards
Ability to develop new formulations of existing molecules and secure IP protection
State-of-the-art unit-dose Form Fill Seal manufacturing
Experienced management team